1Wakabayashi K, Takahashi H. Pathology of familial Parkinson' s disease[J]. Brain Nerve,2007,59(8) :851 - 864.
2Kawahara K, Hashimoto M,Bar - On P,et al. Alpha - synuclein aggregates interfere with parkin solubility and distribution: Role in the pathogenesis of parkinson disease[J]. Biol Chem, 2008, 283 (11):6979 - 6987.
3Marx FP, Soehn AS, Berg D,et al. The proteasomal subunit S6 ATPase is a novel synphilin - 1 interacting protein - implications for Parkinson' s disease[J]. FASEB,2007,21(8) : 1759 - 1767.
4Cookson MR. Parkin's substrates and the pathways leading to neuronal damage[J]. Neummoleeular Med, 2003, 3(1) :1 - 13.
5Vercammen L, Vander Perren A, Vaudano E, et al. Parkin profor Parkinson' s disease[J].Mol Ther, 2006,14 (5) : 716 - 723.
6Poole AC, Thomas RE, Andrews LA,et al. The PINK1/Parkin pathway regulates mitochondrial morphology[J].Proc Natl Acad Sci USA, 2008,105(5) :1638 - 1643.
7Hedrich K, Eskelson C, Wilmot B,et al Distribution, type, and origin of Parkin mutations: Review and case studies[J]. Mov Disord,2004,19(10) : 1146 - 1157.
8Slominski PA, Miloserdova OV, Popova SN, et al. Analysis of deletion mutations in the PARK2 gene in idiopathic Parkinson's disease[J].Genetika, 2003, 39(2): 223-228.
9Bertoli- Avella AM, Giroud - Benitez JL, Akyol A,et al. Novel parkin mutations detected in patients with early - onset Parkinson' s disease[J].Mov Disord, 2005,20(4) :424 - 431.
10Shadrina MI, Semenova EV, Slominsky PA, et al. Effective quantitative real - time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1 - 12 dosage [J]. BMC Med Genet, 2007,8:6.
